UNIVERSITY OF COPENHAGEN Project title Novel Treatments of Neuromuscular Disease Mentor 1 Pontus Gourdon, MSc & PhD,
NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670 | Lifecarenews
NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance Treatments of Neuromuscular Disorders
![Denmark in New York on Twitter: "#DKBIO17 is "a great opportunity for us to broaden our scope and look for investors.” - Thomas H. Pedersen, CEO, NMD Pharma… https://t.co/AUeO5JqgX6" Denmark in New York on Twitter: "#DKBIO17 is "a great opportunity for us to broaden our scope and look for investors.” - Thomas H. Pedersen, CEO, NMD Pharma… https://t.co/AUeO5JqgX6"](https://pbs.twimg.com/media/C9AAsJjWsAEiHz-.jpg)